Enanta Pharmaceuticals, Inc.
ENTA
$8.67
$0.020.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.26M | -22.64M | -22.29M | -28.82M | -22.66M |
| Total Depreciation and Amortization | 1.21M | 1.20M | 889.00K | 479.00K | 594.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.25M | 5.84M | 4.49M | 8.78M | 4.59M |
| Change in Net Operating Assets | 32.30M | 2.11M | 113.00K | 9.16M | 2.70M |
| Cash from Operations | 17.51M | -13.49M | -16.80M | -10.40M | -14.78M |
| Capital Expenditure | -155.00K | -2.54M | -8.75M | -8.95M | -6.54M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.33M | -1.83M | 77.65M | 28.02M | 197.00K |
| Cash from Investing | -26.48M | -4.37M | 68.90M | 19.07M | -6.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 94.00K | 68.00K | 28.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.42M | -6.89M | -5.08M | -7.28M | -6.68M |
| Cash from Financing | -6.42M | -6.89M | -4.99M | -7.22M | -6.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.40M | -24.74M | 47.12M | 1.46M | -27.77M |